Equity Overview
Price & Market Data
Price: $1.25
Daily Change: -$0.12 / 9.63%
Daily Range: $0 - $0
Market Cap: $44,744,956
Daily Volume: 0
Performance Metrics
1 Week: -13.14%
1 Month: 0.85%
3 Months: -5.56%
6 Months: -11.19%
1 Year: -87.16%
YTD: -68.60%
Company Details
Employees: 81
Sector: Health technology
Industry: Biotechnology
Country:
Details
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.